Centene Corporation Third Quarter Earnings Release - CENTENE CORP

Explicit Guidance:

• 2026 Adjusted EPS: Raised to > $5.20 per diluted share (up from > $4.80 previously); excluding non-recurring Q3/Q4 items, the recurring run-rate base is approx. $4.70.
• 2026 Adjusted SG&A Ratio: Midpoint guidance held at 7.2% for the full year (Q3 actual was 6.5%).
• 2026 Investment/Other Income: Guidance held at approx. $1.5 billion.
• 2026 Interest Expense: Lowered to a midpoint of $610 million.
• 2026 Marketplace Pre-tax Margin: Updated to the top of the previous range, 5.0%.
• 2026 Part D (PDP) Pre-tax Margin: Revised upward to the mid-to-high threes (from >3%); expects 2-3% as the initial 2027 starting point before outperformance.
• 2026 Medicaid HBR: Full-year forecast maintained at 93.5%; Q3 actual was 93.6%.
• 2026 Membership: Expected to be down 8–9% year-over-year at year-end due to OB-3 and Florida CMS roll-offs.
• 2027 Outlook: Expects adjusted EPS growth relative to the $4.70 base and the revised $5.20 2026 guidance; formal 2027 guidance to be provided in February 2027.

Business-Segment Outlook:

• Medicaid:
  • HBR: Forecasts slight improvement in 2027 despite OB-3 headwinds as states begin explicitly pricing work requirements and acuity shifts into 2027 rates.
  • Membership: Anticipates continued attrition in Q4 and 2027; expects a "methodical" state approach to eligibility verification smoothing impacts through 2027–early 2028.
  • Rates: Composite rate expectation steady at ~5% for 2026; expecting better alignment with cost experience as 2025 data enters look-back periods.
  • Trends: Observing stabilization in behavioral health and home health trends; expecting continued focus on these drivers in 2027.
• Medicare:
  • Medicare Advantage (MA): On track to reach break-even financial results in 2026 (one year ahead of plan); projects better-than-break-even results in 2027 following a footprint reduction to focus on high-value geographies.
  • Membership: Expects MA membership to be down year-over-year in 2027 as the company constructs a leaner footprint for margin expansion.
  • Part D (PDP): Expects enrollment growth in 2027 driven by a tilt toward enhanced products; pre-tax margins expected to reset to a target range of 2–3% in early 2027 before outperformance.
• Marketplace (Commercial/Ambetter):
  • Margin: Projecting meaningful margin restoration to 5% in 2026; expects further margin expansion in 2027.
  • Membership: Year-end 2026 forecast at 3.2 million; overall exchange market expected to contract slightly in 2027, with membership TBD pending open enrollment results.
  • Product: 2027 strategy includes an expanded product suite with tailored benefits and whole health programs; pricing expected to see increases less significant than 2026.
  • Metal Mix: Anticipates a stable mix relative to 2026, with Bronze remaining a strategic component.

Market and Competitive Outlook:

• Stakeholder Dynamics: States are shifting from retroactive rate adjustments to prospective rate setting that explicitly accounts for work requirement acuity shifts, a material improvement in dialogue compared to the redetermination period.
• Competitive Positioning: Centene expects to outpace industry averages in preventative care and clinical outcome measures; STARS scores (affecting 2028 plan year) are currently 42% at or above 3.5 stars, with advocacy for reforms to support vulnerable populations.
• Regulatory Environment: CMS actively reducing unauthorized enrollments and cracking down on broker fraud; Centene expects these program integrity measures to be fully priced into 2026 guidance with no residual Q4 impact.
• Innovation: Expansion of health-related benefits (food, housing, transportation) demonstrated to lower claims spend by ~$200 per member per month and improve clinical outcomes (HbA1c, BMI).

Macro / Industry Outlook:

• Obamacare (OB-3): Legal non-citizen eligibility terminations begin January 1, 2027; management views the implementation as methodical, with states planning a 60-day notice period to stretch disenrollment impacts across multiple rate cycles and reduce acuity dislocation risks.
• Work Requirements: States broadly opting for methodical eligibility verification; expects smoother membership/acuity flow through 2027 and early 2028.
• Elections: Anticipates potential state leadership changes (39 gubernatorial elections) but expects minimal disruption due to the federal framework and strong state agency relationships.
• 1115 Waivers: No significant impact anticipated from CMS budget neutrality enforcement on overall Medicaid market spending.

Strategic Initiatives:

• Medicare Footprint Restructuring: Executing a strategic reduction in MA footprint to concentrate on geographies with differentiated products and margin potential; impact on 2027 membership expected to be negative but strategically positive for margins.
• Debt Reduction: Total debt reduced to $15.0 billion (from $18.5 billion in late 2024) following $1.1 billion in buybacks/redemptions; debt-to-cap ratio at 41.1%; creating capacity for future growth.
• Workforce Optimization: Executing $480 million in one-time workforce and enterprise optimization costs (mostly in Q3 2026), expected to drive durable SG&A reduction and margin improvement in 2027.
• AI & Automation: Implementing ROI-driven AI and data layer improvements to optimize SG&A and service delivery.
• Commercial Exit: Orderly exit from Health Net commercial group business in California over the next 18–24 months.
• New Product Launches: 2027 Open Enrollment to feature expanded benefit plans and whole health programs (e.g., Nebraska total care food benefit model).

Risks and Headwinds to Outlook:

• OB-3 Acuity Dislocation: Primary risk is a potential gap between 2027 rates and member acuity if states fail to adjust rates prospectively for work requirement-induced health changes.
• Medicaid Enrollment: Continued attrition from OB-3 and the removal of unsatisfactory immigration status populations (e.g., California) poses revenue headwinds.
• PDP Margin Reset: Expectation of PDP pre-tax margins resetting to a lower target (2–3%) in 2027 after outperformance in 2026.
• Policy/Legislative: Uncertainty regarding midterm election impacts on healthcare access policies or "One Big Beautiful Bill" provisions, though management anticipates bipartisan support for safety net programs.
• Rate Lag: Risk that state rate-setting processes remain slower than acuity shifts, potentially delaying margin restoration.

Management Tone on the Future:

• Confidence Level: Highly confident in the trajectory of margin restoration and earnings growth in 2027; describes current outlook as a "new chapter" with "significant opportunity for margin restoration."
• Sentiment: Optimistic about the "stabilization" of core Medicaid trends and the "positive signals" from state rate-setting dialogues; notes a shift in state behavior from reactive to proactive regarding acuity.
• Strategic Clarity: Expressed clear conviction in the MA turnaround (achieved break-even a year early) and the sustainability of the commercial segment's margin recovery.

Miscellaneous:

• Timeline: Formal 2027 financial guidance to be issued during the Q4 earnings call in February 2027.
• Membership Transition: Florida CMS membership roll-off completed on October 1, 2026; no lingering impact expected.
• Cash Flow: $175 million cash available for general corporate use; Q3 cash flow used by operations was $3.7 billion (due to pass-through payments), with YTD provided cash flow at $4.3 billion.